US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Jazz Pharmaceuticals plc - Ordinary Shares
(NQ:
JAZZ
)
235.67
+2.66 (+1.14%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jazz Pharmaceuticals plc - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks
September 29, 2026
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NAS...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Cannabis Stocks: A Profitability Turnaround Is Brewing Beneath Weak Price Action
↗
September 22, 2026
Via
Chartmill
Topics
Cannabis
Jazz Pharmaceuticals Targets $5B Zanidatamab Opportunity as Oncology Revenue Tops $1B
↗
September 20, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) executives outlined the company’s oncology growth strategy, early commercial progress for recently launched therapies and business-development priorities during the...
Via
MarketBeat
Topics
Cannabis
Jazz Pharmaceuticals Sees $3B-$5B Ziihera Opportunity as Pipeline Expands
↗
September 20, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined development and commercial plans for its oncology, epilepsy and sleep franchises during a discussion with Deutsche Bank analyst David Hoang, emphasizing the...
Via
MarketBeat
Topics
Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Stock Trading Below Its Worth
↗
September 02, 2026
Via
Chartmill
Cannabis Rally Turns Selective as Investors Reward Pharma-Tinged Names
↗
August 29, 2026
Via
Chartmill
Topics
Cannabis
Jazz Pharmaceuticals (NASDAQ:JAZZ): A Decent Value Opportunity
↗
August 12, 2026
Via
Chartmill
Cannabis Theme's Hidden Strength: Established Players Outshining Pure Plays
↗
July 30, 2026
Via
Chartmill
Topics
Cannabis
Should You Buy Jazz Pharmaceuticals Stock After Its Actio Acquisition?
↗
September 18, 2026
Actio could make Jazz's growing epilepsy franchise even stronger.
Via
The Motley Fool
3 Cash-Producing Stocks We’re Skeptical Of
September 11, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
Via
StockStory
Topics
Retirement
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead
September 11, 2026
Jazz Pharmaceuticals’s 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was ...
Via
StockStory
Topics
Stocks
1 Value Stock with Exciting Potential and 2 We Brush Off
September 08, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Via
StockStory
Topics
Energy
Retirement
Cannabis Theme Rally Powered by Profitability, Not Pure-Play Speculation
↗
July 03, 2026
Via
Chartmill
Topics
Cannabis
Cannabis Stocks Split into Two Camps: Profitable Operators vs. High-Growth Speculation
↗
June 18, 2026
Via
Chartmill
Topics
Cannabis
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Presents a Decent Value Opportunity with Strong Valuation and Growth Potential
↗
June 09, 2026
Via
Chartmill
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere
September 01, 2026
Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by 2.5% on ...
Via
StockStory
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why
August 31, 2026
What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase...
Via
StockStory
Topics
Artificial Intelligence
Jazz Pharmaceuticals Launches Ziihera After FDA Nod in HER2-Positive GEA
↗
August 25, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) outlined its plans for the U.S. launch of Ziihera following FDA approval of the therapy for first-line HER2-positive unresectable, locally advanced or metastatic...
Via
MarketBeat
Topics
Cannabis
3 Profitable Stocks with Questionable Fundamentals
August 14, 2026
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...
Via
StockStory
Topics
Economy
Jazz Pharmaceuticals (JAZZ) Q2 2026 Earnings Call Transcript
↗
August 10, 2026
Revenue hit $1.2 billion with oncology sales surging and Xywav demand accelerating.
Via
The Motley Fool
Topics
Earnings
5 Revealing Analyst Questions From Jazz Pharmaceuticals’s Q2 Earnings Call
August 10, 2026
Jazz Pharmaceuticals delivered a positive Q2, with a strong 16% year-over-year revenue increase driven primarily by its oncology and rare disease portfolios....
Via
StockStory
Topics
Earnings
Jazz Pharmaceuticals Q2 Earnings Call Highlights
↗
August 03, 2026
Jazz Pharmaceuticals (NASDAQ:JAZZ) reported second-quarter 2026 revenue of $1.21 billion, up 16% from a year earlier, as growth across its sleep, epilepsy and oncology portfolios drove record quarterly...
Via
MarketBeat
Topics
Cannabis
Earnings
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Bullish Q2 CY2026, Guides for Strong Full-Year Sales
August 03, 2026
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 15.5% year on year t...
Via
StockStory
Jazz Pharmaceuticals (JAZZ) Q2 Earnings: What To Expect
August 02, 2026
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after market hours. Here’s what to look for. Jazz Pharmaceuticals be...
Via
StockStory
Topics
Artificial Intelligence
3 Value Stocks with Open Questions
July 16, 2026
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Via
StockStory
3 Overrated Stocks Walking a Fine Line
June 30, 2026
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Via
StockStory
Jazz Pharmaceuticals' Lung Cancer Drug Setback in Late-Stage Trials: Here's Why the Stock Impact May Be More Limited Than It Looks
↗
June 23, 2026
The long-term thesis remains largely unchanged.
Via
The Motley Fool
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
June 17, 2026
From
AbCellera Biologics Inc.
Via
Business Wire
Jazz Pharmaceuticals (JAZZ): Buy, Sell, or Hold Post Q1 Earnings?
June 15, 2026
Jazz Pharmaceuticals has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.7%. The stock now trades at $232.44, mark...
Via
StockStory
Topics
Stocks
Pharmaceuticals Stocks Q1 Recap: Benchmarking Jazz Pharmaceuticals (NASDAQ:JAZZ)
June 14, 2026
Let’s dig into the relative performance of Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings seaso...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
